Non-hormonal Therapies

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the non-hormonal therapies for women’s health market and its likely evolution in the short to mid term and long term.

Chapter 3 provides a general overview of non-hormonal therapies, including a discussion on the key historical milestones in their development. It further includes an overview of the clinical conditions associated with women’s health. Furthermore, it outlines various available treatment modalities for women’s health related conditions (namely surgeries, hormonal therapies and non-hormonal therapies), with key focus on non-hormonal treatment options and prescription therapies.  The chapter concludes with a discussion on the risks and benefits associated with non-hormonal therapies, along with demonstrating their future potential in the market.

Chapter 4 presents a detailed assessment of the current market landscape of non-hormonal therapies along with information on the industry players active in the domain of women’s health. In addition, it features an in-depth analysis of the pipeline molecules, based on a several relevant parameters, such as, current phase of development (marketed, clinical, preclinical and discovery), type of molecule (biologic and small molecule), target indication(bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), purpose of therapy (treatment of disease and management of symptoms), target women population (adult, postmenarchal and premenopausal female, postmenopausal female), mechanism of action (antagonists, agonists, inhibitors and modulators), route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others)and special drug designation(s) awarded (if any).

Chapter 5 provides a detailed review of the players engaged in the development of non-hormonal therapies, along with information on their year of establishment, company size, location of headquarters, and regional landscape.

Chapter 6 features an elaborate discussion on the various strategies that can be adopted by therapy developers engaged in this domain, across key commercialization stages, including prior to drug launch, during drug launch and post-launch. In addition, it presents an in-depth analysis of the key commercialization strategies that have been adopted by developers of non-hormonal therapies approved during the period 2017-2020.

Chapter 7 provides detailed profiles of phase III non-hormonal therapies. Each drug profile provides information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received (if any).

Chapter 8 presents a detailed, geographical clinical trial analysis of completed and ongoing studies focused on non-hormonal therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target indication, geography, type of sponsor, prominent treatment sites and enrolled patient population.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players engaged in the development of non-hormonal therapies, during the period pre2013 - 2020. It includes a brief description on the various types of partnership models including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements and other relevant types of deals, that have been adopted by stakeholders in this domain. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. In addition, the chapter presents details on various funding instances, investments and grants reported within the non-hormonal therapy domain. The chapter includes information on various types of investments, such as seed financing, debt financing, grants, venture capital financing, and others, received by the companies between pre 2013 and 2020, highlighting the growing interest of the strategic investors in this market.

Chapter 10 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. It also includes future sales projections of non-hormonal therapies that are either marketed or in advanced stage of clinical development (phase III). Sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of [A] target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), [B] type of molecule (biologic and small molecule), [C] route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), [D] key geographical regions (North America, Europe and Asia-Pacific). In addition, the chapter presents indication specific value creation analysis.

Chapter 11 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the non-hormonal therapy market.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides the list of companies mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Women’s Health and Affiliated Clinical Conditions
3.2.1. Key Milestones in the Treatment of Women’s Health-related Disorders
3.3. Women’s Health-related Conditions
3.4. Available Treatment Modalities
3.4.1. Surgery
3.4.2. Hormonal Therapies
3.4.3. Non-Hormonal Therapies
3.5. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Non-hormonal Therapies Market: Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Indication
4.2.4. Analysis by Phase of Development and Target Indication
4.2.5. Analysis by Type of Molecule and Target Indication
4.2.6. Analysis by Purpose of Therapy
4.2.7. Analysis by Target Women Population
4.2.8. Analysis by Mechanism of Action
4.2.9. Analysis by Route of Administration

4.3.1. Analysis by Special Designation(s) Awarded

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Non-hormonal Therapies Market: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography
5.3. Key Players: Analysis by Number of Product Candidates
5.4. Big Pharma Initiatives

6. KEY COMMERCIALIZATION STRATEGIES
6.1. Chapter Overview
6.2. Successful Drug Launch Strategy: ROOTS Framework
6.3. Successful Drug Launch Strategy: Product Differentiation
6.4. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
6.5. Approved Non-hormonal Prescription Drugs
6.6. Key Commercialization Strategies Adopted by Companies Focused on Women’s Health
6.6.1. Strategies Adopted Before Therapy Approval
6.6.1.1. Participation in Global Events
6.6.1.2. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
6.6.1.3. Expansion of Target Indication

6.6.2. Strategies Adopted During / Post Therapy Approval
6.6.2.1. Geographical Expansion
6.6.2.2. Participation in Global Events
6.6.2.3. Patient Assistance Programs
6.6.2.4. Awareness Through Product Websites
6.6.2.5. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
6.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
6.7. Concluding Remarks

7. DRUG PROFILES (PHASE III)
7.1. Chapter Overview
7.2. Relugolix
7.3. DARE-BV1 (Clindamycin gel)
7.4. Ovaprene®
7.5. Yselty® (Linzagolix)

7.6. Fezolinetant
7.7. BAY1002670 (Vilaprisan)
7.8. Abaloparatide-TD
7.9. Terconazole (0.4%)
7.10. SCY-078 (Ibrexafungerp)
7.11. VT-1161 (Oteseconazole)
7.12. MV140 (Uromune)
7.13. Orilissa™ (Elagolix)
7.14. EVO100 (Amphora)

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Non-hormonal Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Status
8.3.3. Analysis by Trial Phase
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Target Patient Segment
8.3.6. Analysis by Target Indication
8.3.7. Analysis by Type of Sponsor
8.3.8. Analysis by Geography
8.3.8.1. Analysis by Geography (Pre-2017 and Post 2017)

8.4. Non-Hormonal Therapies: Analysis by Enrolled Patient Population
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Status
8.4.3. Analysis by Trial Phase
8.4.4. Analysis by Geography
8.4.4.1. Analysis by Geography (Pre-2017 and Post 2017)

8.5. Analysis by Study Design

8.6. Concluding Remarks
8.6.1. Emerging Molecules to Watch
8.6.2. Most Important Trials to Watch

9. RECENT DEVELOPMENTS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Non-hormonal Therapies: Recent Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Target Indication
9.3.4. Most Active Players: Analysis by Number of Partnerships
9.3.5. Geographical Analysis
9.3.5.1. Intercontinental and Intracontinental Agreements

9.4. Types of Funding
9.5. Non-Hormonal Therapies: Funding and Investment Analysis
9.5.1. Analysis by Number of Funding Instances
9.5.2. Analysis by Amount Invested
9.5.3. Analysis by Type of Funding

9.5.4. Analysis by Type of Funding and Year
9.5.5. Analysis by Funding Amount and Year
9.5.6. Regional Analysis by Amount Invested
9.5.7. Most Active Players
9.6. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Global Non-hormonal Therapiesfor Women’s Health Market, 2021-2030
10.4.1. Non-hormonal Therapies Market: Analysis by Target Indication
10.4.2. Non-hormonal Therapies Market: Analysis by Type of Molecule
10.4.3. Non-hormonal Therapies Market: Analysis by Route of Administration
10.4.4. Non-hormonal Therapies Market: Analysis by Geography

10.5. Non-hormonal Therapies for Women’s Health Market: Value Creation Analysis
10.5.1. Bacterial Vaginosis
10.5.2. Contraception
10.5.3. Endometriosis
10.5.4. Postmenopausal Osteoporosis
10.5.5. Uterine Fibroids
10.5.6. Vasomotor Symptoms

10.6. Non-hormonal Therapies for Women’s Health Market: Product Wise Sales Forecasts
10.6.1. Nuvessa (Metronidazole)
10.6.1.1. Target Patient Population
10.6.1.2. Sales Forecast
10.6.1.3. Net Present Value

10.6.2. VivaGel (SPL 7013)
10.6.2.1. Target Patient Population
10.6.2.2. Sales Forecast
10.6.2.3. Net Present Value

10.6.3. Solosec (Secnidazole)
10.6.3.1. Target Patient Population
10.6.3.2. Sales Forecast
10.6.3.3. Net Present Value

10.6.4. Tymlos (Abaloparatide)
10.6.4.1. Target Patient Population
10.6.4.2. Sales Forecast
10.6.4.3. Net Present Value

10.6.5. Orilissa
10.6.5.1. Target Patient Population
10.6.5.2. Sales Forecast (Endometriosis)
10.6.5.3. Sales Forecast (Uterine Fibroids)
10.6.5.4. Net Present Value

10.6.6. Osphena (Ospemifene)
10.6.6.1. Target Patient Population
10.6.6.2. Sales Forecast
10.6.6.3. Net Present Value

10.6.7. Evenity(Romosozumab-aqqg)
10.6.7.1. Target Patient Population
10.6.7.2. Sales Forecast
10.6.7.3. Net Present Value

10.6.8. Esmya and Fibristal (Ulipristal acetate)
10.6.8.1. Target Patient Population
10.6.8.2. Sales Forecast
10.6.8.3. Net Present Value

10.6.9. Phexxi (Amphora)
10.6.9.1. Target Patient Population
10.6.9.2. Sales Forecast
10.6.9.3. Net Present Value

10.6.10. Oriahnn
10.6.10.1. Target Patient Population
10.6.10.2. Sales Forecast
10.6.10.3. Net Present Value

10.6.11. Relugolix
10.6.11.1. Target Patient Population
10.6.11.2. Sales Forecast (Uterine Fibroids)
10.6.11.3. Sales Forecast (Endometriosis)
10.6.11.4. Net Present Value

10.6.12. DARE-BV1 (Clindamycin gel)
10.6.12.1. Target Patient Population
10.6.12.2. Sales Forecast
10.6.12.3. Net Present Value

10.6.13. Ovaprene
10.6.13.1. Target Patient Population
10.6.13.2. Sales Forecast
10.6.13.3. Net Present Value

10.6.14. Yselty (Linzagolix)
10.6.14.1. Target Patient Population
10.6.14.2. Sales Forecast (Endometriosis)
10.6014.3. Sales Forecast (Uterine Fibroids)
10.6.14.3. Net Present Value

10.6.15. Fezolinetant
10.6.15.1. Target Patient Population
10.6.15.2. Sales Forecast
10.6.15.3. Net Present Value

10.6.16. BAY1002670 (Vilaprisan)
10.6.16.1. Target Patient Population
10.6.16.2. Sales Forecast
10.6.16.3. Net Present Value

10.6.17. Abaloparatide-TD
10.6.17.1. Target Patient Population
10.6.17.2. Sales Forecast
10.6.17.3. Net Present Value

10.6.18. Terconazole(0.4%)
10.6.18.1. Target Patient Population
10.6.18.2. Sales Forecast
10.6.18.3. Net Present Value

10.6.19. SCY-078 (Ibrexafungerp)
10.6.19.1. Target Patient Population
10.6.19.2. Sales Forecast
10.6.19.3. Net Present Value

10.6.20. VT-1161 (Oteseconazole)
10.6.20.1. Target Patient Population
10.6.20.2. Sales Forecast
10.6.20.3. Net Present Value

10.6.21. MV140 (Uromune)
10.6.21.1. Target Patient Population
10.6.21.2. Sales Forecast
10.6.21.3. Net Present Value

10.6.22. EVO100
10.6.22.1. Target Patient Population
10.6.22.2. Sales Forecast
10.6.22.3. Net Present Value

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES

List Of Figures

Figure 3.1 Key Milestones in the Treatment of Women’s Health-related Disorders
Figure 3.2 Women’s Health-related Conditions
Figure 3.3 Available Treatment Modalities: Non-hormonal Therapies
Figure 4.1 Non-hormonal Therapies: Distribution by Phase of Development
Figure 4.2 Non-hormonal Therapies: Distribution by Type of Molecule
Figure 4.3 Non-hormonal Therapies: Distribution by Target Indication
Figure 4.4 Non-hormonal Therapies: Distribution by Phase of Development and Target Indication
Figure 4.5 Non-hormonal Therapies: Distribution by Type of Molecule and Target Indication
Figure 4.6 Non-hormonal Therapies: Distribution by Purpose of Therapy
Figure 4.7 Non-hormonal Therapies: Distribution by Target Women Population
Figure 4.8 Non-hormonal Therapies: Distribution by Mechanism of Action
Figure 4.9 Non-hormonal Therapies: Distribution by Route of Administration
Figure 4.10 Non-hormonal Therapies: Distribution by Special Designation(s) Awarded
Figure 5.1 Non-hormonal Therapy Developers: Distribution by Year of Establishment
Figure 5.2 Non-hormonal Therapy Developers: Distribution by Company Size
Figure 5.3 Non-hormonal Therapy Developers: Distribution by Location of Headquarters
Figure 5.4 Non-hormonal Therapy Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.5 Non-hormonal Therapy Developers: Big Pharma Initiatives
Figure 6.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 6.2 Successful Drug Launch Strategy: Product Differentiation
Figure 6.3 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
Figure 6.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Women’s Health
Figure 6.5 Approved Non-hormonal Prescription Drugs: Snapshot of Promotional Activities on Product Websites
Figure 6.6 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Figure 8.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2013-2020
Figure 8.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 8.5 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.6 Clinical Trial Analysis: Distribution by Target Indication
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 8.8 Clinical Trial Analysis: Distribution by Geography
Figure 8.9 Clinical Trial Analysis: Distribution by Geography,Pre-2017 and Post-2017
Figure 8.10 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 8.11 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Figure 8.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Location of Trial Site
Figure 8.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography, Pre-2017 and Post 2017
Figure 8.15 Clinical Trial Analysis: Distribution by Study Design
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2021
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Cumulative Trend by Year and Type of Collaboration, 2013-2021
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Merger / Acquisition
Figure 9.5 Partnerships and Collaborations: Distribution by Focus Area
Figure 9.6 Partnerships and Collaborations: Distribution by Target Indication
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.9 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, 2016-2020
Figure 9.10 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2016-2020 (USD Million)
Figure 9.11 Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.12 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 9.13 Funding and Investment Analysis: Distribution by Year and Funding Amount (USD Million)
Figure 9.14 Funding and Investment Analysis: Summary of Investments, 2016-2020 (USD Million)
Figure 9.15 Funding and Investment Analysis: Distribution by Geography
Figure 9.16 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 9.17 Most Active Players: Distribution by Number of Funding Instances, 2016-2020
Figure 9.18 Most Active Players: Distribution by Amount Invested, 2016-2020 (USD Million)
Figure 9.19 Funding and Investment Summary, 2016-2020 (USD Million)
Figure 10.1 Global Non-hormonal Therapies for Women’s Health Market, 2021-2030: Base Case Scenario (USD Million)
Figure 10.2 Non-hormonal Therapies Market: Distribution by Target Indication, 2021, 2025 and 2030
Figure 10.3 Non-hormonal Therapies Market: Distribution by Type of Molecule, 2021, 2025 and 2030
Figure 10.4 Non-hormonal Therapies Market: Distribution by Route of Administration, 2021, 2025 and 2030
Figure 10.5 Non-hormonal Therapies Market: Distribution by Geography, 2021, 2025 and 2030
Figure 10.6 Nuvessa Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.7 VivaGel Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.8 Solosec Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.9 Tymlos Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.10 Orilissa (Endometriosis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.11 Orilissa (Uterine Fibroids) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.12 Osphena Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.13 Evenity Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.14 Esmya and Fibristal Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.15 Phexxi Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.16 Oriahnn Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.17 Relugolix (Uterine Fibroids) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.18 Relugolix (Endometriosis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.19 DARE-BV1 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.20 Ovaprene Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.21 Yselty (Endometriosis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.22 Yselty (Uterine Fibroids) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.23 Fezolinetant Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.24 BAY1002670 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.25 Abaloparatide-TD Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.26 Terconazole (0.4%) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.27 SCY-078 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.28 VT-1161 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.29 MV140 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 10.30 EVO100 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 11.1 Concluding Remarks: Summary of the Current Market Landscape
Figure 11.2 Concluding Remarks: Summary of the Current Developer Landscape
Figure 11.3 Concluding Remarks: Summary of Recent Developments
Figure 11.4 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Women’s Health-related Conditions: Menopause
Table 3.2 Available Treatment Modalities: Surgeries
Table 3.3 Available Treatment Modalities: Hormonal Therapies
Table 4.1 Non-hormonal Therapies Market: Development Pipeline
Table 5.1 Non-hormonal Therapies Market: List of Developers
Table 6.1 Solosec™: Presentations in Conferences Before Product Approval
Table 6.2 Orilissa™: Presentations in Conferences Before Product Approval
Table 6.3 Evenity™: Presentations in Conferences Before Product Approval
Table 6.4 Phexxi™: Presentations in Conferences Before Product Approval
Table 6.5 Oriahnn™: Presentations in Conferences Before Product Approval
Table 6.6 Tymlos™: Presentations in Conferences After Product Approval
Table 6.7 Phexxi™: Presentations in Conferences After Product Approval
Table 6.8 Approved Non-hormonal Therapies: Comparison of Patient Support Services Available on Product Websites
Table 7.1 Non-hormonal Therapy Market: List of Phase III Products
Table 7.2 Drug Profile: Relugolix (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.3 Drug Profile: DARE-BV1 (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.4 Drug Profile: Ovaprene® (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.5 Drug Profile: Yselty® (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.6 Drug Profile: Fezolinetant (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.7 Drug Profile: BAY1002670 (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.8 Drug Profile: Abaloparatide-TD (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.9 Drug Profile: Terconazole (0.4%) (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.10 Drug Profile: SCY-078(Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.11 Drug Profile: VT-1161(Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.12 Drug Profile: MV140 (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.13 Drug Profile: Orilissa (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 7.14 Drug Profile: EVO100 (Overview of Drug, Current Development Status and Clinical Trial Results)
Table 8.1 Clinical Trial Analysis: Emerging Molecules
Table 8.2 Clinical Trial Analysis: Prominent Ongoing Studies
Table 9.1 Non-hormonal Therapy Market: List of Partnerships and Collaborations, Pre 2013-2021
Table 9.2 Non-hormonal Therapy Market: List of Funding and Investments, 2016-2020
Table 10.1 Non-hormonal Therapies: Expected Launch Years of Advanced Stage Drug Candidates
Table 10.2 Nuvessa: Target Patient Population
Table 10.3 Nuvessa: Net Present Value (USD Million)
Table 10.4 VivaGel: Target Patient Population
Table 10.5 VivaGel: Net Present Value (USD Million)
Table 10.6 Solosec: Target Patient Population
Table 10.7 Solosec: Net Present Value (USD Million)
Table 10.8 Tymlos: Target Patient Population
Table 10.9 Tymlos: Net Present Value (USD Million)
Table 10.10 Orilissa: Target Patient Population
Table 10.11 Orilissa: Net Present Value (USD Million)
Table 10.12 Osphena: Target Patient Population
Table 10.13 Osphena: Net Present Value (USD Million)
Table 10.14 Evenity: Target Patient Population
Table 10.15 Evenity: Net Present Value (USD Million)
Table 10.16 Esmya and Fibristal: Target Patient Population
Table 10.17 Esmya and Fibristal: Net Present Value (USD Million)
Table 10.18 Phexxi: Target Patient Population
Table 10.19 Phexxi: Net Present Value (USD Million)
Table 10.20 Oriahnn: Target Patient Population
Table 10.21 Oriahnn: Net Present Value (USD Million)
Table 10.22 Relugolix: Target Patient Population
Table 10.23 Relugolix: Net Present Value (USD Million)
Table 10.24 DARE-BV1: Target Patient Population
Table 10.25 DARE-BV1: Net Present Value (USD Million)
Table 10.26 Ovaprene: Target Patient Population
Table 10.27 Ovaprene: Net Present Value (USD Million)
Table 10.28 Yselty: Target Patient Population
Table 10.29 Yselty: Net Present Value (USD Million)
Table 10.30 Fezolinetant: Target Patient Population
Table 10.31 Fezolinetant: Net Present Value (USD Million)
Table 10.32 BAY1002670: Target Patient Population
Table 10.33 BAY1002670: Net Present Value (USD Million)
Table 10.34 Abaloparatide-TD: Target Patient Population
Table 10.35 Abaloparatide-TD: Net Present Value (USD Million)
Table 10.36 Terconazole (0.4%): Target Patient Population
Table 10.37 Terconazole (0.4%): Net Present Value (USD Million)
Table 10.38 SCY-078: Target Patient Population
Table 10.39 SCY-078: Net Present Value (USD Million)
Table 10.40 VT-1161: Target Patient Population
Table 10.41 VT-1161: Net Present Value (USD Million)
Table 10.42 MV140: Target Patient Population
Table 10.43 MV140: Net Present Value (USD Million)
Table 10.44 EVO100: Target Patient Population
Table 10.45 EVO100: Net Present Value (USD Million)
Table 13.1 Non-hormonal Therapies: Distribution by Phase of Development
Table 13.2 Non-hormonal Therapies: Distribution by Type of Molecule
Table 13.3 Non-hormonal Therapies: Distribution by Target Indication
Table 13.4 Non-hormonal Therapies: Distribution by Phase of Development and Target Indication
Table 13.5 Non-hormonal Therapies: Distribution by Type of Molecule and Target Indication
Table 13.6 Non-hormonal Therapies: Distribution by Purpose of Therapy
Table 13.7 Non-hormonal Therapies: Distribution by Target Women Population
Table 13.8 Non-hormonal Therapies: Distribution by Mechanism of Action
Table 13.9 Non-hormonal Therapies: Distribution by Route of Administration
Table 13.10 Non-hormonal Therapies: Distribution by Special Designation(s) Awarded
Table 13.11 Non-hormonal Therapy Developers: Distribution by Year of Establishment
Table 13.12 Non-hormonal Therapy Developers: Distribution by Company Size
Table 13.13 Non-hormonal Therapy Developers: Distribution by Location of Headquarters
Table 13.14 Non-hormonal Therapy Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 13.15 Non-hormonal Therapy Developers: Big Pharma Initiatives
Table 13.16 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2013-2020
Table 13.17 Clinical Trial Analysis: Distribution by Trial Status
Table 13.18 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 13.20 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 13.21 Clinical Trial Analysis: Distribution by Target Indication
Table 13.22 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.23 Clinical Trial Analysis: Distribution by Geography
Table 13.24 Clinical Trial Analysis: Distribution by Geography, Pre-2017 and Post 2017
Table 13.25 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 13.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Table 13.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 13.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Location of Trial Site
Table 13.29 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography , Pre-2017 and Post 2017
Table 13.30 Clinical Trial Analysis: Distribution by Study Design
Table 13.31 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2021
Table 13.32 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.33 Partnerships and Collaborations: Cumulative Trend by Year and Type of Collaboration, 2013-2021
Table 13.34 Partnerships and Collaborations: Distribution by Type of Acquisition / Merger
Table 13.35 Partnerships and Collaborations: Distribution by Focus Area
Table 13.36 Partnerships and Collaborations: Distribution by Target Indication
Table 13.37 Most Active Players: Distribution by Number of Partnerships
Table 13.38 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 13.39 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, 2016-2020
Table 13.40 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2016-2020 (USD Million)
Table 13.41 Funding and Investment Analysis: Distribution by Type of Funding
Table 13.42 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 13.43 Funding and Investment Analysis: Distribution by Year and Funding Amount (USD Million)
Table 13.44 Funding and Investment Analysis: Distribution by Geography
Table 13.45 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 13.46 Most Active Players: Distribution by Number of Funding Instances, 2016-2020
Table 13.47 Most Active Players: Distribution by Amount Invested, 2016-2020 (USD Million)
Table 13.48 Funding and Investment Summary, 2016-2020 (USD Million)
Table 13.49 Global Non-hormonal Therapies for Women’s Health Market, 2021-2030: Base Case Scenario (USD Million)
Table 13.50 Non-hormonal Therapies Market: Distribution by Target Indication, 2021, 2025 and 2030
Table 13.51 Non-hormonal Therapies Market: Distribution by Type of Molecule, 2021, 2025 and 2030
Table 13.52 Non-hormonal Therapies Market: Distribution by Route of Administration, 2021, 2025 and 2030
Table 13.53 Non-hormonal Therapies Market: Distribution by Geography, 2021, 2025 and 2030
Table 13.54 Nuvessa Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.55 VivaGel Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.56 Solosec Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.57 Tymlos Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.58 Orilissa (Endometriosis) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.59 Orilissa (Uterine Fibroids) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.60 Osphena Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.61 Evenity Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.62 Esmya and Fibristal Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.63 Phexxi Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.64 Oriahnn Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.65 Relugolix (Uterine Fibroids) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.66 Relugolix (Endomteriosis) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.67 DARE-BV1 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.68 Ovaprene Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.69 Yselty (Endometriosis) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.70 Yselty (Uterine Fibroids) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.71 Fezolinetant Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.72 BAY1002670 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.73 Abaloparatide-TD Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.74 Terconazole (0.4%) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.75 SCY-078 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.76 VT-1161 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.77 MV140 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.78 EVO100 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million) 

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. AbbVie
2. Actavis
3. Adjuvant Capital
4. Aisling Capital
5. Allergan
6. Amgen
7. Amplity Health
8. Arcadia Securities
9. Aspire Capital Fund
10. Astellas Pharma
11. Avomeen
12. Azure Biotech
13. Bayer
14. BB Biotech
15. Boehringer Ingelheim
16. Broadfin Capital
17. Brookline Capital Markets
18. Cantor Fitzgerald
19. Ceek Women's Health
20. Celmatix
21. Chugai Pharmaceutical
22. Cidara Therapeutics
23. DAFNA Capital Management
24. Daré Bioscience
25. Duchesnay
26. Eli Lilly
27. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
28. Evofem Biosciences
29. Evotec
30. Exeltis
31. Ferring Pharmaceuticals
32. First Manhattan Co.
33. Forest Laboratories
34. Fougera Pharmaceuticals
35. Gedea Biotech 
36. Gedeon Richter
37. Ghost Tree Capital
38. Great Point Partners
39. Guggenheim Securities
40. H.C. Wainwright & Co.
41. Hammock Pharmaceuticals (acquired by Element Nutritional Sciences)
42. Hansoh Pharma
43. Health Decisions
44. Hennepin Life Sciences
45. Inmunotek
46. Inovio Pharmaceuticals
47. Intralytix, the Eliava Foundation 
48. ITF Pharma
49. Jiangsu Hengrui Medicine
50. KaNDy Therapeutics (acquired by Bayer)
51. Kindeva Drug Delivery
52. Kissei Pharmaceutical
53. Korea Investment Partners (KIP)
54. Ladenburg Thalmann
55. Ligand Pharmaceuticals
56. Lupin Pharmaceuticals
57. Medtech4Health
58. Merck Sharp & Dohme
59. Milana Pharm
60. Mitsubishi Tanabe Pharma
61. Medical Research Commercialisation Fund (MRCF)
62. Mycovia Pharmaceuticals
63. Myovant Sciences
64. National Holdings
65. National Securities Corporation
66. Neurocrine Biosciences
67. New Enterprise Associates
68. New Leaf Venture Partners
69. NovaDigm Therapeutics
70. Novartis Pharmaceuticals
71. Noven Pharmaceuticals
72. ObsEva
73. Ogeda
74. Omega Funds
75. Oxford Finance
76. PDL BioPharma
77. Pfizer
78. Prosight Capital
79. Puissance Capital
80. QUE Oncology
81. Radius Health
82. Repros Therapeutics (acquired by Allergan)
83. Roche
84. Sanofi-Aventis
85. SCYNEXIS
86. Shionogi
87. Sofinnova Ventures
88. Sphera Global Healthcare Fund
89. Square 1 Bank 
90. Starpharma
91. Strategic Science & Technologies
92. Sumitomo Dainippon Pharma
93. Swelife
94. Symbiomix Therapeutics (acquired by Lupin)
95. Takeda Pharmaceutical
96. TriLogic Pharma
97. Uniseed
98. Venrock Healthcare Capital Partners
99. Vinnova Financing
100. Vinnova Grants 
101. WBB Securities
102. Woodford Investment Management
103. Xanodyne Pharmaceuticals
104. Yaso Therapeutics